For business leaders, corporate strategists, and growth-focused teams – this report delivers deep market intelligence, forecasts, segmentation, and competitor insights to guide your decisions through 2034.
How has the neulasta grown historically, and what trends indicate future expansion?
The neulasta market size has XX (HCAGR) in recent years. It will grow from $XX million in 2024 to $XX million in 2025 at a compound annual growth rate (CAGR) of XX%. The growth in the historic period can be attributed to the rising prevalence of chemotherapy-induced neutropenia, increased cancer incidence globally, growing awareness of neutropenia risks during cancer treatment, availability of supportive government funding for biologics, and early adoption of biologics in developed regions.
The neulasta market size is expected to see XX (FCAGR) in the next few years. It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX%. The growth in the forecast period can be attributed to the expansion of biosimilars in emerging markets, rising demand for cost-effective cancer-supportive care, growing healthcare expenditure worldwide, increasing approvals for biosimilars by regulatory agencies, and rising patient awareness of biosimilar alternatives. Major trends in the forecast period include the development of prefilled syringes for easier administration advances in drug delivery systems such as on-body injectors, the adoption of digital platforms for patient education, the use of AI in biologics R&D and supply chain optimization, and strategic partnerships between biologic and biosimilar firms.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20159&type=smp
Which key factors are driving the expansion of the neulasta industry?
The rising incidence of cancer is driving the growth of the neulasta market going forward. Cancer is a group of diseases characterized by abnormal cell growth, which can spread to other body parts. The increasing prevalence of cancer is driven by factors such as aging populations, unhealthy lifestyles, and environmental factors. Pegfilgrastim biosimilars, such as neulasta, are critical for cancer patients undergoing chemotherapy to prevent chemotherapy-induced neutropenia by stimulating white blood cell production and reducing the risk of infections. For instance, in August 2024, according to the Australian Institute of Health and Welfare, an Australian-based national agency for information and statistics on Australia’s health and welfare, by 2034, Australia is projected to have approximately 209,000 new cancer diagnoses, a significant increase from the estimated 169,000 cases expected in 2024. Additionally, in 2024, cancer is anticipated to account for about 3 out of every ten deaths in the country. Therefore, the rising incidence of cancer will drive the neulasta market.
How is the neulasta market segmented by product, application, and end-user?
The neulasta market covered in this report is segmented –
1) By Indication: Chemotherapy-Induced Neutropenia, Bone Marrow Transplantation, Other Indications
2) By Formulation: Injectable Solution, Pre-Filled Syringes Or Pens
3) By Distribution Channel: Hospitals, Oncology Clinics, Specialty Pharmacies, Home Healthcare Services
4) By End User Patients: Adult Patients, Pediatric Patients
View The Full Market Report:
https://www.thebusinessresearchcompany.com/report/neulasta-global-market-report
Which major trends are influencing the growth of the neulasta industry?
The key trend in the neulasta market is the development of drug delivery technologies, such as prefilled autoinjectors, to gain a competitive edge in the industry. Prefilled autoinjectors are self-injection devices preloaded with medication, designed for convenient and easy patient self-administration. For example, in March 2023, Coherus Biosciences, a US-based biopharmaceutical company, announced that the FDA approved a single-dose, prefilled autoinjector version of its pegfilgrastim biosimilar, Udenyca (pegfilgrastim-cbqv), for the treatment and prevention of febrile neutropenia, a common complication of chemotherapy. This autoinjector allows patients to receive pegfilgrastim the day after chemotherapy, reducing the risk of febrile neutropenia. The device features push-on-skin activation for reliable, immediate delivery of a full pegfilgrastim dose.
Which leading companies are dominating the neulasta market landscape?
Major companies operating in the neulasta market include Amgen Inc.
Which geographic areas are expected to offer the highest growth opportunities in theneulasta market?
North America was the largest region in the neulasta market in 2024. The regions covered in the neulasta market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
How Can Companies Use The Neulasta Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20159
Need Customized Data On Neulasta Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/customise?id=20159&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
